Thrombosis Research
Volume 126, Issue 2 , Pages 124-129 , August 2010

Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats

  • Noriko Konishi

      Affiliations

    • Pharmacology Research Laboratories, Takeda Pharmaceutical Company Ltd., Osaka, Japan
    • ,
  • Katsuhiko Hiroe

      Affiliations

    • Pharmacology Research Laboratories, Takeda Pharmaceutical Company Ltd., Osaka, Japan
    • ,
  • Masaki Kawamura

      Affiliations

    • Takeda Global Research & Development Center, Inc., IL, USA
    • Corresponding Author InformationCorresponding author. Takeda Global Research & Development Center, Inc., 675 North Field Drive, Lake Forest, IL, 60045 USA. Tel.: +1 847 582 3621; fax: +1 224 554 7945.

Received 11 December 2009 ,Revised 19 March 2010 ,Accepted 7 April 2010.

References 

  1. Corti R, Farkouh ME, Badimon JJ. The vulnerable plaque and acute coronary syndromes. Am J Med. 2002;113:668–680
  2. Cairns JA, Théroux P, Lewis HD, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. Chest. 2001;119:228S–252S
  3. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809–1840
  4. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction–2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002;106:1893–1900
  5. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2003;24:28–66
  6. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  7. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
  8. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–1189
  9. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969–974
  10. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25, 307 patients. Eur Heart J. 2006;27:519–526
  11. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, et al. ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362:789–797
  12. Hong TT, Huang J, Driscoll E, Lucchesi BR. The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study). J Cardiovasc Pharmacol. 2005;46:526–533
  13. Kawasaki T, Sato K, Sakai Y, Hirayama F, Koshio H, Taniuchi Y, et al. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb Haemost. 1998;79:410–416
  14. Hayashi M, Matsuo A, Nakamoto H, Aisaka K. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals. Eur J Pharmacol. 2001;412:61–66
  15. Wong PC, Crain EJ, Watson CA, Zaspel AM, Wright MR, Lam PY, et al. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J Pharmacol Exp Ther. 2002;303:993–1000
  16. Wong PC, Crain EJ, Watson CA, Wexler RR, Lam PY, Quan ML, et al. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. J Thromb Thrombolysis. 2007;24:43–51
  17. Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost. 2008;6:1736–1741
  18. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, et al. APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877–2885
  19. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374:29–38
  20. Walsh PN, Schmaier AH. Platelet-coagulant protein interactions. In:  Colman RW,  Hirsh J,  Marder VJ, et al. editor. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed.. Philadelphia: JB Lippincott Co; 1994;p. 629–651
  21. Chu V, Brown K, Colussi D, Gao J, Bostwick J, Kasiewski C, et al. Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Thromb Res. 2001;103:309–324
  22. Rezaie AR. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost. 2003;89:112–121
  23. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514–521
  24. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48:1–22
  25. Weitz JI, Cao C, Eriksson B, Fisher WD, Kupfer S, Raskob GE, et al. Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty. Blood. 2009;114:170
  26. Hérault JP, Dol F, Gaich C, Bernat A, Herbert JM. Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat. Thromb Haemost. 1999;81:957–960
  27. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999;100:1667–1672
  28. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban–an oral, direct factor Xa inhibitor–are not affected by aspirin. J Clin Pharmacol. 2006;46:981–990
  29. Kawasaki J, Katori N, Kodaka M, Miyao H, Tanaka KA. Electron microscopic evaluations of clot morphology during thrombelastography. Anesth Analg. 2004;99:1440–1444
  30. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958–965
  31. Leon C, Ravanat C, Freund M, Cazenave JP, Gachet C. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol. 2003;23:1941–1947
  32. Vicic WJ, Lages B, Weiss HJ. Release of human platelet factor V activity is induced by both collagen and ADP and is inhibited by aspirin. Blood. 1980;56:448–455
  33. Chesney CM, Pifer D, Colman RW. Subcellular localization and secretion of factor V from human platelets. Proc Natl Acad Sci U S A. 1981;78:5180–5184
  34. Mousa SA, Khurana S, Forsythe MS. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists. Arterioscler Thromb Vasc Biol. 2000;20:1162–1167
  35. Mousa SA, Forsythe MS. Comparison of the effect of different platelet GPIIb/IIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography. Thromb Res. 2001;104:49–56
  36. Greilich PE, Alving BM, O'Neill KL, Chang AS, Reid TJ. A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients. Anesth Analg. 1997;84:31–38
  37. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches. Vasc Med. 1998;3:231–239
  38. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006;113:722–731
  39. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115:15–20

PII: S0049-3848(10)00230-6

doi: 10.1016/j.thromres.2010.04.005

Thrombosis Research
Volume 126, Issue 2 , Pages 124-129 , August 2010

Article Tools

* Image Usage & Resolution